Adjuvanted herpes zoster subunit vaccine

作者：Aerssens Annelies; Leroux Roels Geert

来源：Future Virology, 2016, 11(1): 5-18.

DOI：10.2217/fvl.15.105

• adjuvant
• adjuvant systems
• AS01(B)
• CD4(+) T cells
• CD8(+) T cells
• herpes zoster
• shingles
• postherpetic neuralgia
• varicella zoster virus

This review highlights the characteristics of a candidate herpes zoster (HZ) vaccine (HZ/su, GlaxoSmithKline Vaccines) that consists of 50 mu g recombinant glycoprotein E (gE) of varicella zoster virus adjuvanted with AS01(B). It is well tolerated and shows a clinically acceptable tolerability profile. It strongly enhances pre-existing gE-specific CD4(+) T-cell and anti-gE antibody responses in older adults and immunocompromised persons. Administration of two doses 2 months apart reduces the risk of HZ by 97.2% in adults >= 50 years. This effect does not diminish with increasing age. Long-term persistence of its efficacy still needs to be determined. This candidate HZ vaccine may become an alternative for the high-dose live-attenuated varicella zoster virus vaccine for the prevention of HZ in older persons and in immunocompromised patients in whom the use of live-attenuated vaccines is contraindicated.

• 出版日期2016